by Josh Hoffman, Zymergen Co-Founder and CEO

We’ve got some amazing momentum as a business, and today’s announcement of additional funding is a powerful accelerant. We have $300 million in new investment from Baillie Gifford, Baron Capital and others, as well as returning investors supporting and still several months left in our Series D round. This not only strengthens Zymergen’s financial position, but is further proof that our approach to developing superior products through biology is an unmatched opportunity.

This new influx fuels the release of products across consumer electronics, agriculture, and consumer care, further accelerating Zymergen’s disruption of the…


Dr. Kathleen Shelton, Chief Technology Officer of FMC

For more than 130 years, FMC has been rooted in agriculture and innovation. My team of more than 800 scientists and associates are guiding one of the most robust discovery and development pipelines in the industry, fueled by our passion for bringing new crop protection technologies to growers around the world.

With increasing food demand for a growing population and more stringent regulations globally, we’re entering a new era of innovation in agriculture. FMC has an established and effective molecule discovery process that begins with chemistry. As a leader in science and material innovation, Zymergen manages the largest, most complete…


by Zach Serber, Chief Science Officer

Zymergen is joining forces with FMC, a leading agricultural sciences company, to change the very nature of crop protection…with nature. FMC provides truly innovative solutions to growers around the world with a product portfolio that’s market-driven, and they’ve got a strong development pipeline in crop protection, plant health, and professional pest and turf management. Together, we’re creating breakthrough crop protection products, and developing a new — and faster — natural products discovery process along the way.

Since their founding, FMC has been focused on developing innovative and sustainable solutions to the toughest challenges facing…


by John Warner, Zymergen Distinguished Research Fellow

Non-covalent derivatization isn’t exactly something you hear in day-to-day conversation, even among scientists. Today — almost 30 years after I first used the term to describe an alternative to traditional synthesis practices at the Polaroid Corporation — it remains equal parts tongue twister and brain twister. Not because it’s necessarily difficult, but because it’s a departure from the traditional high-temperature, high-pressure synthetic techniques that most chemists are taught in school. Said differently, it requires approaching the problem an entirely new way, unlearning what many of us were taught, and ‘doing’ chemistry in an…


by Richard Pieters, President, Products

These are challenging times — and certainly unprecedented. Like so many other companies, Zymergen has done whatever we can to help reduce the spread and find a treatment for COVID-19. Everything from volunteering our equipment and expertise to exploring potential treatments in our own labs. Despite all the headwinds we are facing, I am pleased to share a bright spot from last week.

On Wednesday morning, Zymergen announced our first standalone, commercially available product called HYALINE — a revolutionary bio-generated specialty film in the polyimide family. Hyaline is unique, both because it is created from…


by Josh Hoffman, CEO and Co-Founder

Earlier today we announced the release of HYALINE — a revolutionary new bio-fabricated film that we believe will completely transform the electronics industry. Developed in partnership with Sumitomo Chemical, the Hyaline products have been successfully tested in flexible circuits, display touch sensors and printable electronics. You can read the full announcement here.

As it turns out, making impossible new materials from biology is hard — and making and delivering new materials from biology at a commercial scale is even harder. But Zymergen has the capabilities and talent to move incredibly quickly from discovery to…


by Josh Hoffman, CEO, Zymergen

Earlier today, we publicly announced our acquisition of enEvolv, the global leader in ultra-high throughput microbial screening and engineering. With this acquisition, we will greatly accelerate our delivery of new, high-value products to market by 20% — and that’s only the beginning. By merging enEvolv’s powerful platform technology with our existing genome engineering, automation and machine learning capabilities, we will dramatically improve our ability to discover, design and commercialize breakthrough biologically-manufactured products.

Our metagenomic search space is vast — one of the largest databases on the planet. The enEvolv technology is orders of magnitude better…


by Josh Hoffman, CEO, Zymergen

The World Economic Forum and McKinsey recently published a whitepaper in which they recognize Zymergen as a “lighthouse company”, helping drive what they characterize as the Fourth Industrial Revolution (they also presented us with a lighthouse award, which a number of my colleagues shared from Davos). As the paper’s authors explain it, advances in manufacturing — from the technical to the financial to operational — are driving this Fourth Industrial Revolution. I’d like to offer another driver; one that I would argue is far more powerful and consequential. …


At Zymergen, we use biology to create never-before imagined materials. As we continue to scale and build our growing pipeline of next generation products, we’re proud to announce that we’ve appointed Jay Flatley, Chairman of the Board of Illumina, and Sandra E. Peterson, former Group Worldwide Chairman for Johnson & Johnson, to Zymergen’s Board of Directors. Jay will serve as Lead Independent Director.

As we set out to change the world, we are committed to assembling a world-class roster of board members who can help us uphold the highest standards of fairness, accountability, responsibility and transparency. …


At Zymergen, we apply AI or machine learning techniques to many aspects of our high-throughput microbial genome assembly and testing systems and practices. Aaron Kimball, our CTO, offers his thoughts on what lessons we’ve learned as a result of this AI journey, and how these can be generalized to a broader business context. In part one, we discussed the advantages can AI bring to organizations. Here in part two, we’ll dive into the challenges and costs of its implementation.

The challenge of implementing AI

The benefits described in part I are applicable to any number of domains of human effort and industry. In any workplace…

Zymergen

Zymergen is a science and material innovation company rethinking biology and reimagining the world.

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store